<DOC>
	<DOCNO>NCT00864175</DOCNO>
	<brief_summary>This single arm , modify dose escalation , open label trial objective : ( 1 ) Determining safe optimal dose INCB007839 combination trastuzumab docetaxel ( 2 ) Determining clinical efficacy safety INCB007839 combination trastuzumab docetaxel .</brief_summary>
	<brief_title>Open Label Trial INCB07839 Determine Effect Safety INCB007839 Plus Trastuzumab HER2 Positive Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically cytologically confirm metastatic breast carcinoma HER2 positive Measurable disease define RECIST criterion Life expectancy great equal 6 month Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Received anticancer medication 28 day prior enrollment study Received anticancer medication cancer breast cancer within 6 month prior enrollment study . History deep venous thrombosis within last year Contraindication low dose warfarin therapy Clinically significant cardiomyopathy Prior treatment INCB007839 trastuzumab lapatinib</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>